Skip to main content
Top
Published in: Head and Neck Pathology 1/2020

01-03-2020 | Sarcoma | Special Issue: Soft Tissue

Soft Tissue Special Issue: Biphenotypic Sinonasal Sarcoma: A Review with Emphasis on Differential Diagnosis

Authors: John Gross, Karen Fritchie

Published in: Head and Neck Pathology | Issue 1/2020

Login to get access

Abstract

Biphenotypic sinonasal sarcoma is an anatomically restricted low-grade malignant neoplasm with dual neural and myogenic differentiation composed of a monotonous population of spindled cells with herringbone/fascicular architecture. These tumors demonstrate a unique immunoprofile with relatively consistent S100-protein and actin expression in conjunction with more variable desmin, myogenin and myoD1 staining. SOX10 is uniformly negative. Genetically, the majority of tumors harbor PAX3-MAML3 fusions, with alternate PAX3 partners including FOXO1, NCOA1, NCOA2 and WWTR1. Although the differential diagnosis of BSNS is broad, careful morphologic inspection together with targeted ancillary studies is often sufficient to arrive at the correct diagnosis. As these tumors have significant local recurrence rates but lack metastatic potential, awareness and accurate diagnosis of this rare and newly described neoplasm is critical for appropriate management.
Literature
1.
go back to reference Lewis JT, Oliveira AM, Nascimento AG, et al. Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol. 2012;36:517–25.CrossRef Lewis JT, Oliveira AM, Nascimento AG, et al. Low-grade sinonasal sarcoma with neural and myogenic features: a clinicopathologic analysis of 28 cases. Am J Surg Pathol. 2012;36:517–25.CrossRef
2.
go back to reference Andreasen S, Bishop JA, Hellquist H, et al. Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity. Virchows Arch. 2018;473:615–26.CrossRef Andreasen S, Bishop JA, Hellquist H, et al. Biphenotypic sinonasal sarcoma: demographics, clinicopathological characteristics, molecular features, and prognosis of a recently described entity. Virchows Arch. 2018;473:615–26.CrossRef
3.
go back to reference Fritchie KJ, Jin L, Wang X, et al. Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histopathology. 2016;69:930–6.CrossRef Fritchie KJ, Jin L, Wang X, et al. Fusion gene profile of biphenotypic sinonasal sarcoma: an analysis of 44 cases. Histopathology. 2016;69:930–6.CrossRef
4.
go back to reference Huang SC, Ghossein RA, Bishop JA, et al. Novel PAX3-NCOA1 fusions in biphenotypic sinonasal sarcoma With focal rhabdomyoblastic differentiation. Am J Surg Pathol. 2016;40:51–9.CrossRef Huang SC, Ghossein RA, Bishop JA, et al. Novel PAX3-NCOA1 fusions in biphenotypic sinonasal sarcoma With focal rhabdomyoblastic differentiation. Am J Surg Pathol. 2016;40:51–9.CrossRef
5.
go back to reference Jo VY, Marino-Enriquez A, Fletcher CDM, et al. Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics. Am J Surg Pathol. 2018;42:1275–85.CrossRef Jo VY, Marino-Enriquez A, Fletcher CDM, et al. Expression of PAX3 distinguishes biphenotypic sinonasal sarcoma from histologic mimics. Am J Surg Pathol. 2018;42:1275–85.CrossRef
6.
go back to reference Kakkar A, Rajeshwari M, Sakthivel P, et al. Biphenotypic sinonasal sarcoma: a series of six cases with evaluation of role of beta-catenin immunohistochemistry in differential diagnosis. Ann Diagn Pathol. 2018;33:6–10.CrossRef Kakkar A, Rajeshwari M, Sakthivel P, et al. Biphenotypic sinonasal sarcoma: a series of six cases with evaluation of role of beta-catenin immunohistochemistry in differential diagnosis. Ann Diagn Pathol. 2018;33:6–10.CrossRef
7.
go back to reference Le Loarer F, Laffont S, Lesluyes T, et al. Clinicopathologic and molecular features of a series of 41 biphenotypic sinonasal sarcomas expanding their molecular spectrum. Am J Surg Pathol. 2019;43:747–54.CrossRef Le Loarer F, Laffont S, Lesluyes T, et al. Clinicopathologic and molecular features of a series of 41 biphenotypic sinonasal sarcomas expanding their molecular spectrum. Am J Surg Pathol. 2019;43:747–54.CrossRef
8.
go back to reference Rooper LM, Huang SC, Antonescu CR, et al. Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear beta-catenin positivity and absence of SOX10 expression. Hum Pathol. 2016;55:44–50.CrossRef Rooper LM, Huang SC, Antonescu CR, et al. Biphenotypic sinonasal sarcoma: an expanded immunoprofile including consistent nuclear beta-catenin positivity and absence of SOX10 expression. Hum Pathol. 2016;55:44–50.CrossRef
9.
go back to reference Wang X, Bledsoe KL, Graham RP, et al. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet. 2014;46:666–8.CrossRef Wang X, Bledsoe KL, Graham RP, et al. Recurrent PAX3-MAML3 fusion in biphenotypic sinonasal sarcoma. Nat Genet. 2014;46:666–8.CrossRef
10.
go back to reference Wong WJ, Lauria A, Hornick JL, et al. Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosom Cancer. 2016;55:25–9.CrossRef Wong WJ, Lauria A, Hornick JL, et al. Alternate PAX3-FOXO1 oncogenic fusion in biphenotypic sinonasal sarcoma. Genes Chromosom Cancer. 2016;55:25–9.CrossRef
11.
go back to reference Cannon RB, Wiggins RH, Witt BL, et al. Imaging and outcomes for a new entity: low-grade sinonasal sarcoma with neural and myogenic features. J Neurol Surg Rep. 2017;78:e15–9.CrossRef Cannon RB, Wiggins RH, Witt BL, et al. Imaging and outcomes for a new entity: low-grade sinonasal sarcoma with neural and myogenic features. J Neurol Surg Rep. 2017;78:e15–9.CrossRef
12.
go back to reference Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008;12:2281–94.CrossRef Wang Q, Fang WH, Krupinski J, et al. Pax genes in embryogenesis and oncogenesis. J Cell Mol Med. 2008;12:2281–94.CrossRef
13.
go back to reference Lang D, Lu MM, Huang L, et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature. 2005;433:884–7.CrossRef Lang D, Lu MM, Huang L, et al. Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature. 2005;433:884–7.CrossRef
14.
go back to reference Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol. 2009;44:85–97.CrossRef Medic S, Ziman M. PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol. 2009;44:85–97.CrossRef
15.
go back to reference Nakazaki H, Reddy AC, Mania-Farnell BL, et al. Key basic helix-loop-helix transcription factor genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. Dev Biol. 2008;316:510–23.CrossRef Nakazaki H, Reddy AC, Mania-Farnell BL, et al. Key basic helix-loop-helix transcription factor genes Hes1 and Ngn2 are regulated by Pax3 during mouse embryonic development. Dev Biol. 2008;316:510–23.CrossRef
16.
go back to reference Heffner DK, Gnepp DR. Sinonasal fibrosarcomas, malignant schwannomas, and "Triton" tumors. A clinicopathologic study of 67 cases. Cancer. 1992;70:1089–101.CrossRef Heffner DK, Gnepp DR. Sinonasal fibrosarcomas, malignant schwannomas, and "Triton" tumors. A clinicopathologic study of 67 cases. Cancer. 1992;70:1089–101.CrossRef
17.
go back to reference Hellquist HB, Lundgren J. Neurogenic sarcoma of the sinonasal tract. J Laryngol Otol. 1991;105:186–90.CrossRef Hellquist HB, Lundgren J. Neurogenic sarcoma of the sinonasal tract. J Laryngol Otol. 1991;105:186–90.CrossRef
18.
go back to reference Gil Z, Fliss DM, Voskoboimik N, et al. Two novel translocations, t(2;4)(q35;q31) and t(X;12)(q22;q24), as the only karyotypic abnormalities in a malignant peripheral nerve sheath tumor of the skull base. Cancer Genet Cytogenet. 2003;145:139–43.CrossRef Gil Z, Fliss DM, Voskoboimik N, et al. Two novel translocations, t(2;4)(q35;q31) and t(X;12)(q22;q24), as the only karyotypic abnormalities in a malignant peripheral nerve sheath tumor of the skull base. Cancer Genet Cytogenet. 2003;145:139–43.CrossRef
19.
go back to reference Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–21.CrossRef Ducatman BS, Scheithauer BW, Piepgras DG, et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986;57:2006–21.CrossRef
20.
go back to reference Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227–32.CrossRef Lee W, Teckie S, Wiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227–32.CrossRef
21.
go back to reference Rohrich M, Koelsche C, Schrimpf D, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131:877–87.CrossRef Rohrich M, Koelsche C, Schrimpf D, et al. Methylation-based classification of benign and malignant peripheral nerve sheath tumors. Acta Neuropathol. 2016;131:877–87.CrossRef
22.
go back to reference Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4–13.CrossRef Schaefer IM, Fletcher CD, Hornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29:4–13.CrossRef
23.
go back to reference Cleven AH, Sannaa GA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–90.CrossRef Cleven AH, Sannaa GA, Briaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29:582–90.CrossRef
24.
go back to reference Le Guellec S, Macagno N, Velasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017;30:1677–87.CrossRef Le Guellec S, Macagno N, Velasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017;30:1677–87.CrossRef
25.
go back to reference Pekmezci M, Cuevas-Ocampo AK, Perry A, et al. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017;30:1710–9.CrossRef Pekmezci M, Cuevas-Ocampo AK, Perry A, et al. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017;30:1710–9.CrossRef
26.
go back to reference Asano N, Yoshida A, Ichikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology. 2017;70:385–93.CrossRef Asano N, Yoshida A, Ichikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumours. Histopathology. 2017;70:385–93.CrossRef
27.
go back to reference Prieto-Granada CN, Wiesner T, Messina JL, et al. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40:479–89.CrossRef Prieto-Granada CN, Wiesner T, Messina JL, et al. Loss of H3K27me3 expression is a highly sensitive marker for sporadic and radiation-induced MPNST. Am J Surg Pathol. 2016;40:479–89.CrossRef
28.
go back to reference Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27–36.CrossRef Agaram NP, LaQuaglia MP, Alaggio R, et al. MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Mod Pathol. 2019;32:27–36.CrossRef
29.
go back to reference Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol. 1992;16:229–35.CrossRef Cavazzana AO, Schmidt D, Ninfo V, et al. Spindle cell rhabdomyosarcoma. A prognostically favorable variant of rhabdomyosarcoma. Am J Surg Pathol. 1992;16:229–35.CrossRef
30.
go back to reference Carter CS, East EG, McHugh JB. Biphenotypic sinonasal sarcoma: a review and update. Arch Pathol Lab Med. 2018;142:1196–201.CrossRef Carter CS, East EG, McHugh JB. Biphenotypic sinonasal sarcoma: a review and update. Arch Pathol Lab Med. 2018;142:1196–201.CrossRef
31.
go back to reference Lasota J, Felisiak-Golabek A, Aly FZ, et al. Nuclear expression and gain-of-function beta-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker. Mod Pathol. 2015;28:715–20.CrossRef Lasota J, Felisiak-Golabek A, Aly FZ, et al. Nuclear expression and gain-of-function beta-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker. Mod Pathol. 2015;28:715–20.CrossRef
32.
go back to reference Haller F, Bieg M, Moskalev EA, et al. Recurrent mutations within the amino-terminal region of beta-catenin are probable key molecular driver events in sinonasal hemangiopericytoma. Am J Pathol. 2015;185:563–71.CrossRef Haller F, Bieg M, Moskalev EA, et al. Recurrent mutations within the amino-terminal region of beta-catenin are probable key molecular driver events in sinonasal hemangiopericytoma. Am J Pathol. 2015;185:563–71.CrossRef
33.
go back to reference Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5.CrossRef Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5.CrossRef
34.
go back to reference Agaram NP, Zhang L, Sung YS, et al. Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol. 2016;40:1407–16.CrossRef Agaram NP, Zhang L, Sung YS, et al. Recurrent NTRK1 gene fusions define a novel subset of locally aggressive lipofibromatosis-like neural tumors. Am J Surg Pathol. 2016;40:1407–16.CrossRef
35.
go back to reference Suurmeijer AJH, Dickson BC, Swanson D, et al. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosom Cancer. 2018;57:611–21.CrossRef Suurmeijer AJH, Dickson BC, Swanson D, et al. A novel group of spindle cell tumors defined by S100 and CD34 co-expression shows recurrent fusions involving RAF1, BRAF, and NTRK1/2 genes. Genes Chromosom Cancer. 2018;57:611–21.CrossRef
36.
go back to reference Davis JL, Lockwood CM, Stohr B, et al. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol. 2019;43:435–45.CrossRef Davis JL, Lockwood CM, Stohr B, et al. Expanding the spectrum of pediatric NTRK-rearranged mesenchymal tumors. Am J Surg Pathol. 2019;43:435–45.CrossRef
37.
go back to reference Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology. 2018;73:634–44.CrossRef Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology. 2018;73:634–44.CrossRef
Metadata
Title
Soft Tissue Special Issue: Biphenotypic Sinonasal Sarcoma: A Review with Emphasis on Differential Diagnosis
Authors
John Gross
Karen Fritchie
Publication date
01-03-2020
Publisher
Springer US
Keyword
Sarcoma
Published in
Head and Neck Pathology / Issue 1/2020
Electronic ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-019-01092-4

Other articles of this Issue 1/2020

Head and Neck Pathology 1/2020 Go to the issue